This paper is only available as a PDF. To read, Please Download here.
Article info
Publication history
Accepted:
February 11,
2023
Received:
February 3,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Conflicts of interest
Surein Arulananda has received speaker fees from Merck-Sharpe & Dohme, Astra Zeneca, Roche, Bristol-Myers Squibb, Merck Serono, travel support from Astra Zeneca, Roche, Merck-Sharpe & Dohme and has been on an advisory board for Boehringer Ingelheim, Roche. Yang Wang has no conflicts of interest.
CREDIT statement
Conceptualization; YW and SA Data curation YW and SA; Formal analysis YW and SA; Project administration YW and SA; Supervision SA; Roles/Writing - original draft YW; Writing - review & editing SA. A
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint InhibitorsJTO Clinical and Research Reports
- PreviewLandmark trials testing immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e. ≥2) Eastern Cooperative Oncology Group performance status (ECOG PS). We sought to evaluate the impact of ECOG PS on clinical outcomes and health care utilization in NSCLC patients treated with ICI in real-world practice.
- Full-Text
- Preview
